A Comparison of Chemoembolization Combination With and Without Radiotherapy for Unresectable Hepatocellular Carcinoma
- 1 September 2004
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in The Cancer Journal
- Vol. 10 (5), 307-316
- https://doi.org/10.1097/00130404-200409000-00008
Abstract
This study evaluated the effect of transcatheter arterial chem-oembolization combined with external beam radiotherapy on the response rates and sur vival of patients with unresectable hepato-cellular carcinoma. Transcatheter arterial chemoembolization is frequently used for the treatment of this cancer, but complete or massive necrosis is seldom observed. Historically, radiotherapy for hepatocellular carcinoma has yielded poor long-term survival. Multimodality therapy has been initiated in an effort to improve survival statistics. We retrospectively studied 203 patients with unresectable hepa-tocellular carcinoma, who were free of tumor thrombus, lymph node involvement, or extrahepatic metastasis based on computed tomography scans of the chest and abdomen. Among the 203 patients who received transcatheter ar terial chemoembolization as initial therapy, 54 also received combination therapy with external beam radiotherapy. Tumor response rate, survival, and failure patterns were analyzed and compared between the two groups. Objective responses (complete and partial responses) on computed tomography study were obser ved in 31% and 76% of patients in the non-radiotherapy and radiotherapy groups, respectively. Overall survival rates in the patients in the radiotherapy group were 71.5%, 42.3%, and 24.0% at 1, 2, and 3 years, respectively, improved over the non-radiotherapy group rates of 59.6%, 26.5%, and 11.1% at 1, 2, and 3 years, respectively. Intrahepatic failure was lower in the radiotherapy group than in the non-radiotherapy group, but the difference was not significant. Side effects from radiotherapy were common, but rarely severe. This retrospective study suggests that the outcome of unresectable hepatocellular carcinoma can be influenced by radiation therapy, but a prospective randomized trial would be necessary to draw definitive conclusions.Keywords
This publication has 17 references indexed in Scilit:
- Comparison between chemoembolization combined with radiotherapy and chemoembolization alone for large hepatocellular carcinomaWorld Journal of Gastroenterology, 2003
- Comparison between radioimmunotherapy and external beam radiation therapy for patients with hepatocellular carcinomaEuropean Journal of Nuclear Medicine and Molecular Imaging, 2002
- Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinomaHepatology, 2002
- Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trialThe Lancet, 2002
- Long-Term Results With Multimodal Adjuvant Therapy and Liver Transplantation for the Treatment of Hepatocellular Carcinomas Larger Than 5 CentimetersAnnals of Surgery, 2002
- Current status of liver transplantation for hepatocellular cancerThe American Journal of Surgery, 2002
- Randomized Control Trials on Chemoembolization for Hepatocellular CarcinomaJournal of Clinical Gastroenterology, 2001
- Local radiotherapy with or without transcatheter arterial chemoembolization for patients with unresectable hepatocellular carcinomaInternational Journal of Radiation Oncology*Biology*Physics, 2000
- Combined transcatheter arterial chemoembolization and local radiotherapy of unresectable hepatocellular carcinomaInternational Journal of Radiation Oncology*Biology*Physics, 1999
- Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: a multicenter randomized trialJournal of Hepatology, 1998